Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Seattle Genetics, Inc.May 21 2011

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from its brentuximab vedotin (ADCETRIS™) and SGN-75 programs will be reported at the upcoming American Society of Clinical Oncology (ASCO) 2011 Annual Meeting being held June 3-7, 2011 in Chicago, IL. A summary of the company's ASCO poster presentations is below and full abstracts can be accessed on the ASCO website at www.asco.org.

Brentuximab Vedotin

Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL)

• Monday, June 6, 1:00 p.m.-5:00 p.m. Central Time (CT)
• Abstract #8031
• First author: Dr. Robert W. Chen, City of Hope, Duarte, CA

Durable remissions with brentuximab vedotin: Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)

• Monday, June 6, 1:00 p.m.-5:00 p.m. CT
• Abstract #8032
• First author: Dr. Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA

SGN-75

The effect of SGN-75, a novel antibody-drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study

• Monday, June 6, 8:00 a.m.-12:00 p.m. CT
• Abstract #3071
• First author: Dr. John A. Thompson, Seattle Cancer Care Alliance, Seattle, WA